DSGN Quote, Financials, Valuation and Earnings

Phio Pharmaceuticals has a net margin of -- compared to Design Therapeutics's net margin of --. Design Therapeutics's return on equity of -- beat Phio Pharmaceuticals's return on equity of --.

Design Therapeutics has a consensus price target of --, signalling upside risk potential of 54.87%. On the other hand Phio Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 2030.18%. Given that Phio Pharmaceuticals has higher upside potential than Design Therapeutics, analysts believe Phio Pharmaceuticals is more attractive than Design Therapeutics.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Phio Pharmaceuticals has a beta of 1.511, suggesting its more volatile than the S&P 500 by 51.085%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Phio Pharmaceuticals pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Phio Pharmaceuticals quarterly revenues of --. Design Therapeutics's net income of -$13M is lower than Phio Pharmaceuticals's net income of -$1.5M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Phio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus -- for Phio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -- compared to Design Therapeutics's net margin of -54.2%. Design Therapeutics's return on equity of -- beat PTC Therapeutics's return on equity of --.

Design Therapeutics has a consensus price target of --, signalling upside risk potential of 54.87%. On the other hand PTC Therapeutics has an analysts' consensus of $58.36 which suggests that it could grow by 32.81%. Given that Design Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Design Therapeutics is more attractive than PTC Therapeutics.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.129%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Design Therapeutics's net income of -$13M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Design Therapeutics's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 3.73x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Traws Pharma has a net margin of -- compared to Design Therapeutics's net margin of -14868.42%. Design Therapeutics's return on equity of -- beat Traws Pharma's return on equity of -124.39%.

Design Therapeutics has a consensus price target of --, signalling upside risk potential of 54.87%. On the other hand Traws Pharma has an analysts' consensus of -- which suggests that it could fall by -25.56%. Given that Design Therapeutics has higher upside potential than Traws Pharma, analysts believe Design Therapeutics is more attractive than Traws Pharma.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Traws Pharma has a beta of 1.132, suggesting its more volatile than the S&P 500 by 13.246%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Traws Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Traws Pharma pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Traws Pharma quarterly revenues of $57K. Design Therapeutics's net income of -$13M is lower than Traws Pharma's net income of -$8.5M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Traws Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 32.60x for Traws Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -- compared to Design Therapeutics's net margin of -36.72%. Design Therapeutics's return on equity of -- beat Voyager Therapeutics's return on equity of 9.12%.

Design Therapeutics has a consensus price target of --, signalling upside risk potential of 54.87%. On the other hand Voyager Therapeutics has an analysts' consensus of $17.10 which suggests that it could grow by 213.76%. Given that Voyager Therapeutics has higher upside potential than Design Therapeutics, analysts believe Voyager Therapeutics is more attractive than Design Therapeutics.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.053%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Voyager Therapeutics quarterly revenues of $24.6M. Design Therapeutics's net income of -$13M is lower than Voyager Therapeutics's net income of -$9M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 8.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 1.86x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.